AZ News from the Street 2018

Discussion in 'AstraZeneca' started by anonymous, Jan 11, 2018 at 11:43 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Dead cat bounce is a good one.
    Astra needs a bounce
     

  2. anonymous

    anonymous Guest

    Markets go up and down but notice that CNN and the rest of the Democrat's propaganda machine jumped on the 1000 pt drop and immediately blamed Trump and his policies and seemed thrilled about it. But not a word when the market was going up 1000 pts every week and setting 71 record highs along the way and all since the November election. Oh yeah, I remember, that was a result of Obama's policies only when it goes down is it Trump's fault.
    You know the liberal lying media is cheering for the economy and stock market to tank. Isn't that sad?
     
  3. anonymous

    anonymous Guest

    Trump's son takes a 20 minute meeting because someone offers dirt on Hillary and that was collusion. Hillary spends $35 million and hires a foreign spy to pay the Russian operatives to give them dirt on Trump and then leaks it to the press and the FBI that actually takes it seriously. And Hillary lies for months saying they had nothing to do with it until the courts force them to show the bank records and presto, the Clinton campaign paid for it but then they said they weren't aware and never approved it. Oh but that wouldn't be collusion with the Russians. Oh no.
     
  4. anonymous

    anonymous Guest

    EOY one time charges in order to take advantage of better tax credits, impacted earnings negatively for Q4. Americans will have more to spend and coropirations will have more cash after tax in 2018. Too bad AZ isn’t domiciles in US. No soup for you!
     
  5. anonymous

    anonymous Guest


    I didn't make that one up. It is an old Wall Street Trader saying. Animal rightists may get offended in today's environment. It refers to the aftermath of a crash/correction. The meaning is that if you drop one from high enough, even a dead cat will bounce. In the aftermath of a large drop, there is often a temporary uptick as bargain hunters come in seeking to buy low. If they are right that the bottom has been found then they have created some profit. If they are wrong and there is another leg down of drop to go, then they have lost.
     
  6. anonymous

    anonymous Guest

    Markets ended flat today. The market may be in the process of putting in at least a temporary bottom. I would expect the market to test these recent lows again in several weeks to a month. That is barring any dramatic news on the economy before that. We have to hope that compromises on spending bills and debt limits hold. Government shutdowns and debt defaults would certainly qualify as such events. Right now it looks like those dramatic events won't happen, so things may quiet down for a while. The slower acting effects of rising interest rates and accelerating inflation are still out there corroding the economy however, we'll see if those factors can be brought under control. Interest rates on the 10Y treasury is almost back to the point that triggered the market decline. The Federal Reserve only control rates for short term vehicles, the bond market itself sets rates for longer term products, the Fed can not fully control the yields on longer bonds, so stay tuned.
     
  7. anonymous

    anonymous Guest

    The market is down big again today so far. Was yesterday's apparent recovery just a dead cat bounce and there is another leg down still to go, or is this still part the bottom finding process?

    Bad news, the 10Y treasury yield is back up to nearly 3% again. In normal times that would be a fine rate, but this time it is coming off of very low rates.

    Good news, the plan to avoid a government shutdown and debt default is in place, if it can be pushed across the finish line.

    We will just have to wait and see what happens.
     
  8. anonymous

    anonymous Guest

    The house has the necessary votes to pass it! The worry is inflation and the bond market, the overall outlook for the economy is strong which is a reason the market is nervous and correcting itself.
    AZ stock is doing well up $34.52 as of now..
     
  9. anonymous

    anonymous Guest

    AZ is holding up well, relatively speaking, in this steep decline.


    Another old Wall Street Adage is "never try to catch a falling knife"

    You should wait until it hits the ground, and only then try to pick it up. Otherwise you very might get hurt.
     
  10. anonymous

    anonymous Guest

    Yikes!! Another 1000 points shaved off the DOW today!!

    I thought the intra-session lows from a few days ago would be tested in a few week or so, but they were tested today and they badly failed the test!!

    This knife is still falling, don't try to catch it!! You might get hurt!!
     
  11. anonymous

    anonymous Guest

    Some AZ news:

    AstraZeneca AZN announced that the FDA has approved a second indication for its PD-L1 inhibitor, Imfinzi. It is now approved for unresectable Stage III non-small cell lung cancer (“NSCLC”). The drug is meant for patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy." AstraZeneca AZN announced that the FDA has approved a second indication for its PD-L1 inhibitor, Imfinzi. It is now approved for unresectable Stage III non-small cell lung cancer (“NSCLC”). The drug is meant for patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

    AstraZeneca’s shares have returned 16.3% in the past year, outperforming the industry’s gain of 13% in that period.

    The approval comes on the back of impressive progression free survival data (“PFS”) in patients treated with Imfinzi in the phase III PACIFIC study. Data showed that Imfinzi improved PFS by more than 11 months in comparison to placebo in the concerned patient population. The median PFS was 16.8 months for patients on Imfinzi compared with 5.6 months for placebo.

    Imfinzi was launched in the United States for the first indication - second line advanced bladder cancer - in May 2017. The drug has brought in sales of $19 million in 2017.

    Per the press release, globally 30% of NSCLC patients have Stage III disease with the majority of the patients diagnosed with unresectable tumors. Currently, the patients are treated with chemotherapy and radiation therapy, followed by active surveillance to monitor for progression. Imfinzi, the first immunotherapy approved in this indication, will be a better treatment option for these patients and represents a better market opportunity for AstraZeneca.

    AstraZeneca is also developing Imfinzi as monotherapy as well as combination therapy for treatment of NSCLC in first-line or adjuvant setting. The drug is also being developed for several other cancer indications including head and neck, gastric, pancreatic, hepatocellular and blood cancers.

    However, lung cancer is a competitive segment as it attracts several players due to the huge market opportunity. Novartis NVS and Roche received approval for their respective drugs, Zykadia and Alecensa, in 2017 for treating metastatic NSCLC in first-line setting.

    Other immunotherapies for treating various cancer indications include Bristol-Myers Squibb Company’s BMY Opdivo and Merck & Co.’s MRK Keytruda.
     
  12. anonymous

    anonymous Guest

    Some general stock market news:

    Art Cashin warns there's a chance the market could retest February's correction lows
    • Wall Street vet Art Cashin warns that there's a chance the stock market could retest the massive lows seen earlier this month.
    • "There's probably a 35 percent chance that we still have to retest earlier lows from a week and a half to two weeks ago," UBS' director of floor operations at the NYSE says.
    Closely followed trader Art Cashin warned on Wednesday that there's a chance the stock market could retest the massive lows seen earlier this month.

    Stocks sold off earlier this month, after a higher-than-expected wage number in January's jobs report sparked fears of inflation and rising interest rates. Wall Street eventually bottomed out on Feb. 8, briefly plunging into 10 percent correction territory. The market had been up for six straight sessions before Tuesday's decline.

    "There's probably a 35 percent chance that we still have to retest earlier lows from a week and a half to two weeks ago," said Cashin, UBS director of floor operations at the New York Stock Exchange. Most similar pullbacks have rarely "ended in a V shape," rising straight back up after lows, Cashin said.

    "You wind up with a little bit of a W," Cashin told CNBC's "Squawk on the Street." "The market has kind of shrugged its shoulders at seasonal patterns," periodic fluctuations that occur regularly based on a particular season.
     
  13. anonymousl

    anonymousl Guest

    Anything is possible! Doesn’t take a genius to make that prediction...
     
  14. anonymous

    anonymous Guest

    Flu Mist is back

    (Reuters) - AstraZeneca Plc (AZN.L) (AZN.N) said on Wednesday an advisory committee of the U.S. Centers for Disease Control and Prevention recommended the use of its FluMist Quadrivalent vaccine in the upcoming flu season, reversing its earlier position.

    In 2016, the agency advised doctors not to use the nasal spray citing data that demonstrated it was not effective at preventing influenza.

    The latest recommendation follows results from a U.S. study in young children that showed vaccines containing a 2017-2018 strain of H1N1 flu virus performed better than the 2015-2016 strain that had shown decreased effectiveness, AstraZeneca said.

    The announcement arrives in the midst of the most severe flu season the country has experienced in decades. As of Feb. 3, 63 infants died this season, the CDC reported earlier, adding outbreaks were likely to linger for several weeks and cause more deaths.

    The company said limited quantities of the vaccine continue to be available for the current season.

    FluMist, made by an AstraZeneca subsidiary, was first approved in 2003.
     
  15. anonymous

    anonymous Guest

    Markets down again bigly today. Trade war talk has severely spooked the market. The whole tariff premise is flawed from the start, try to enhance jobs for 100,000 steel workers, but then lose 7 million jobs in companies that use the steel. There are of course better and more subtle ways to manage these issues rather than using the sledge hammer of tariffs.
    This is probably just yet another intentional distraction to attempt to change the topic of conversation from all of the other major problems they are having and these tariffs will probably never actually be enacted. It definitely spooked the markets though. In the meantime, 2018 is negative for the year yet again, wiping out trillions in market assets. Please Twitter, cut off the account of this menace.
     
  16. anonymous

    anonymous Guest

    Some AZ news, they are splitting MedImmune up into two companies with a different focus.

    AstraZeneca's MedImmune spins out biotech to focus on autoimmune candidates

    Published 01 March 2018
    MedImmune, the global biologics research and development arm of AstraZeneca, is creating a stand-alone company for early-stage inflammation and autoimmunity biologics.

    Viela Bio, which will get a funding of up to $250m, will develop drugs for severe autoimmune diseases by targeting the fundamental causes of each disease.

    Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital will lead the investment in the new biotech company with AstraZeneca to remain as its largest minority shareholder.

    Viela Bio will be based in Gaithersburg in the US state of Maryland. It will start off with three clinical and three pre-clinical potential new medicines, contributed by MedImmune.

    AstraZeneca executive vice president and MedImmune president Bahija Jallal said: “Our goal is always to find a way for the science to advance. By establishing Viela Bio, we are creating an optimal environment for the continued development of our promising early-stage biologics portfolio in inflammation and autoimmunity.

    “This has the potential to bring the most benefit to patients and will allow us to maintain focus on our three main therapy areas.”

    Included in the list of molecules to be owned by Viela Bio is inebilizumab, which is an anti-CD19 monoclonal antibody. The molecule is currently undergoing a phase 2 trial for the treatment of neuromyelitis optica, a rare condition that affects both the optic nerve and spinal cord in about five in 100,000 people.

    Inebilizumab had secured orphan drug designation from both the US Food and Drug Administration and the European Medicines Agency, in 2016 and 2017, respectively.

    The list of molecules to be owned by Viela Bio does not include anifrolumab, AstraZeneca’s candidate for treating lupus, which currently is in phase 3 development.

    Viela Bio CEO Bing Yao said: “Viela Bio shows great potential, launching with a very robust pipeline with multiple novel molecules in inflammation and autoimmunity.

    “This is combined with a strong, expanding team that has in-depth scientific and clinical development expertise and the ability to bring important, innovative medicines to patients.”
     
  17. anonymous

    anonymous Guest

    Markets getting nervous about inflation?

    JP Morgan co-president warns of 'deep correction' for stocks totaling as much as 40% over next few years
    • "The equity market has some way to go for the next year to two," said J.P. Morgan's Daniel Pinto. "But then, if there is a correction, it could be a deep correction."
    • Pinto noted that market corrections tend to be the result of many factors, but he highlighted central bank activity as a potential pitfall for markets.
    • "Those are the things you want to watch: That inflation doesn't go up too fast, that forces the central banks to go a little faster and quickly than they're doing now," he added.
    Thomas Franck | @tomwfranck
    Published 2 Hours Ago Updated 1 Hour Ago

    A grizzly bear roams through the Hayden Valley in Yellowstone National Park in Wyoming.
    J.P. Morgan co-president Daniel Pinto believes equity markets could see as much as a 40 percent correction within the next few years.

    "The equity market has some way to go for the next year to two," Pinto said in an interview with Bloomberg TV. "But then, if there is a correction, it could be a deep correction. It could be between 20 and 40 percent depending on the valuations at the time. The most important thing for someone like us is just to be prepared."

    Pinto's comments come a month after fears of burgeoning inflation and rallying interest rates caused a spike in market volatility and sent the Dow Jones industrial average tumbling into correction territory. Many Wall Street economists expect prices to steadily increase throughout 2018 given tight labor market conditions.

    February proved another strong month for job creation, with ADP and Moody's Analytics reporting that companies added 235,000 jobs over the course of the month.

    Pinto noted that market corrections tend to be the result of many factors, but he highlighted central bank activity as a potential pitfall for global markets.

    "I think those are the things you want to watch: That inflation doesn't go up too fast, that forces the central banks to go a little faster and quickly than they're doing now," the bank executive explained. "So you want to watch economic indicators, that they don't show that the economy is sliding down and you want to look at some geopolitical issues."

    Markets consider a March rate hike from the Federal Reserve nearly certain, judging by trading in the Fed funds futures market. Subsequent hikes are anticipated in June and a third likely coming in September, according to the CME's FedWatch tracker.
     
  18. anonymous

    anonymous Guest

    Where does ZS-9 fit in? Saw 2019 launch at NSM, but approval in 2018.
     
  19. anonymous

    anonymous Guest

    ZS-9 is not going to contribute very soon with these setbacks, but my guess is that it would stay with Medi

    The FDA has rejected AstraZeneca’s hyperkalemia drug ZS-9 for the second time in 12 months. The news marks a further blow for a program AstraZeneca saw giving it a sizable share of a $6 billion (€5.5 billion) market when it acquired the asset in its $2.7 billion buyout of ZS Pharma.

    Next to nothing has gone right for AstraZeneca and ZS-9 since then. The problems began in May when the FDA rejected the drug—which was already being reviewed at the time AstraZeneca bought ZS Pharma—on the basis of observations made by its inspectors during a preapproval assessment of the ZS-9 manufacturing facility. Ten months later, AstraZeneca is still being dogged by regulatory concerns about the production of ZS-9.

    AstraZeneca revealed scant details in a release to disclose its latest FDA complete response letter (CRL). But in noting the rejection followed an FDA inspection of the ZS-9 production plant, AstraZeneca has again pointed to manufacturing problems as the source of its woes.

    In between the two CRLs, AstraZeneca picked up regulatory approval for ZS-9 in the European Union. But it needs to access the U.S. market if it is to begin racking up the sort of sales required to justify the price it paid for ZS Pharma in 2015. At that time, the takeover looked like a direct route to blockbuster sales for AstraZeneca, and a blow to Relypsa’s attempts to corner the hyperkalemia market with its ZS-9 competitor Veltassa.

    Today, 16 months after the ZS Pharma buyout, Relypsa has sold out to Vifor Pharma for $1.5 billion and AstraZeneca is still yet to get its drug on the market in the U.S.

    Vifor, the specialty pharma unit of Galenica, is using Veltassa and the commercial footprint it acquired to spearhead its attempts to become a strong enough business to thrive after its parent company spins off its pharmacy business. And it is committing serious cash to the cause, with the 2017 budget for the launch and ramp up of Veltassa coming in at upward of $260 million. AstraZeneca’s missteps are helping Vifor’s efforts.

    At the time of the last CRL, AstraZeneca thought recently-submitted manufacturing data not yet reviewed by the FDA could help its case but the problems at the plant persist. AstraZeneca said it is working with the FDA to fix the outstanding issues “as soon as possible.”
     
  20. anonymous

    anonymous Guest

    Another market rout today. DOW down 725 points today. Combination of rising interest rates and trade war tirades is one excuse. A new big omnibus spending bill or a looming government shutdown? Pick your poison. Dow back down below 24,000 points again.